Transcript
A (0:03)
When did making plans get this complicated? It's time to streamline with WhatsApp, the secure messaging app that brings the whole group together. Use polls to settle dinner plans, send event invites and pin messages so no one forgets mom 60th and never miss a meme or milestone. All protected with end to end encryption. It's time for WhatsApp message privately with everyone. Learn more@WhatsApp.com.
B (0:31)
Netflix, Mattel and Hilton what today's earnings signal about international travel and shoppers plans for Christmas. LinkedIn's chief economist joins me to discuss the labor market and what's up with those open job ghost postings. And as MPIC maker Novo Nordisk has drama in the boardroom, let's see who's shaking things up for Wednesday, October 22, it's Brew Market Daily and I'm Ann Berry. More market details to come. But first, for a lesson in irony, let's take a look at the drama unfolding right now at Novo Nordisk. Now, the pharma giant famous for its blockbuster weight loss drugs, Wegovy and Ozempic, recently cut its profit growth forecast for the third time this year. So who is it who seems to care the most about its profit problem? Ironically, a non profit, specifically the Novo Nordisk foundation, which owns 28% of the company's shares but actually controls 75% of voting power. The foundation has wanted faster decision making from the board, which it says has been too slow to recognize market challenges like increased competition. And as a result of the foundation's frustration, seven of Novo's 12 board members will leave the board representing wholesale change at the very top of Novo Nordisk just after a new CEO was appointed only two months ago. So will all this commotion get Novo back on track? Well, the company, whose market cap was once bigger than the GDP of its native Denmark, has seen its stock drop over 50% in the past 12 months. Since CEO Mike Dar stepped up in August, Novo Nordisk has put its running shoes on. It's getting some buzz for the launch of an oral version of Wegovy. After years, a sleepy ramp cost reduction is in process with 9,000 jobs being eliminated. And Novo has announced billions of dollars of acquisition spend in the past eight weeks. Now this is the kind of dramatic change we associate with aggressive activist hedge funds shaking things up, not a non profit foundation. Then we take a step back. It does sort of make sense because it really is self interest that motivates these kinds of things. The foundation does want maximum value from its shareholdings to fund its charitable programs. So it's a dramatic but rare lesson in how an active board member, whatever their background, can and should, challenge public companies to make tough moves when times get tough. Now, there's going to be a lot going on with Novo Nordisk from here. We're going to keep watching. Coming up, it's earnings season. We explore why shares of Mattel are up today but down elsewhere, including at Netflix. But first, a word from our sponsor, Capital Group. This morning our producer John and I were talking about some other podcasts that we listen to.
